Literature DB >> 20220093

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.

Scott E James1, Philip D Greenberg, Michael C Jensen, Yukang Lin, Jinjuan Wang, Lihua E Budde, Brian G Till, Andrew A Raubitschek, Stephen J Forman, Oliver W Press.   

Abstract

We investigated relationships among chimeric TCR (cTCR) expression density, target Ag density, and cTCR triggering to predict lysis of target cells by cTCR(+) CD8(+) T human cells as a function of Ag density. Triggering of cTCR and canonical TCR by Ag could be quantified by the same mathematical equation, but cTCR represented a special case in which serial triggering was abrogated. The magnitude of target lysis could be predicted as a function of cTCR triggering, and the predicted minimum cTCR density required for maximal target lysis by CD20-specific cTCR was experimentally tested. cTCR density below approximately 20,000 cTCR/cell impaired target lysis, but increasing cTCR expression above this density did not improve target lysis or Ag sensitivity. cTCR downmodulation to densities below this critical minimum by interaction with Ag-expressing targets limited the sequential lysis of targets in a manner that could be predicted based on the number of cTCRs remaining. In contrast, acute inhibition of lysis of primary, intended targets (e.g., leukemic B cells) due to the presence of an excess of secondary targets (e.g., normal B cells) was dependent on the Ag density of the secondary target but occurred at Ag densities insufficient to promote significant cTCR downmodulation, suggesting a role for functional exhaustion rather than insufficient cTCR density. This suggests increasing cTCR density above a critical threshold may enhance sequential lysis of intended targets in isolation, but will not overcome the functional exhaustion of cTCR(+) T cells encountered in the presence of secondary targets with high Ag density.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220093      PMCID: PMC2896691          DOI: 10.4049/jimmunol.0903701

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies.

Authors:  L Alvarez-Vallina; S J Russell
Journal:  Hum Gene Ther       Date:  1999-03-01       Impact factor: 5.695

2.  Formation of TCR dimers/trimers as a crucial step for T cell activation.

Authors:  M F Bachmann; M Salzmann; A Oxenius; P S Ohashi
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

3.  Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events.

Authors:  Y Itoh; B Hemmer; R Martin; R N Germain
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

4.  The duration of antigenic stimulation determines the fate of naive and effector T cells.

Authors:  G Iezzi; K Karjalainen; A Lanzavecchia
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

5.  T cell activation determined by T cell receptor number and tunable thresholds.

Authors:  A Viola; A Lanzavecchia
Journal:  Science       Date:  1996-07-05       Impact factor: 47.728

6.  Conjugation between cloned human NK cells (H7.8) and K562/MOLT4 tumor cell systems: saturability, binding parameters, and population distribution of conjugates.

Authors:  L Cabrera; J Galvez; F Lajarin; G Rubio; P Aparicio; P Garcia-Peñarrubia
Journal:  Cell Immunol       Date:  1996-04-10       Impact factor: 4.868

7.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

Authors:  S R Riddell; P D Greenberg
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

8.  CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Authors:  M Jensen; G Tan; S Forman; A M Wu; A Raubitschek
Journal:  Biol Blood Marrow Transplant       Date:  1998       Impact factor: 5.742

9.  Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway.

Authors:  S Isaaz; K Baetz; K Olsen; E Podack; G M Griffiths
Journal:  Eur J Immunol       Date:  1995-04       Impact factor: 5.532

10.  Selective activation of the calcium signaling pathway by altered peptide ligands.

Authors:  J Sloan-Lancaster; T H Steinberg; P M Allen
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  18 in total

1.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

Review 2.  Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Authors:  Cameron J Turtle
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

Review 3.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

4.  Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.

Authors:  Silvia Arcangeli; Maria Caterina Rotiroti; Marco Bardelli; Luca Simonelli; Chiara Francesca Magnani; Andrea Biondi; Ettore Biagi; Sarah Tettamanti; Luca Varani
Journal:  Mol Ther       Date:  2017-05-04       Impact factor: 11.454

Review 5.  Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.

Authors:  Anna Konstorum; Anthony T Vella; Adam J Adler; Reinhard C Laubenbacher
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

6.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 7.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

8.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Authors:  Alec J Walker; Robbie G Majzner; Ling Zhang; Kelsey Wanhainen; Adrienne H Long; Sang M Nguyen; Paola Lopomo; Marc Vigny; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Mol Ther       Date:  2017-07-01       Impact factor: 11.454

9.  A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Authors:  Jennifer D Stone; David H Aggen; Andrea Schietinger; Hans Schreiber; David M Kranz
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

10.  NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Authors:  Seth M Pollack; Yonqing Li; Megan J Blaisdell; Erik A Farrar; Jeffrey Chou; Benjamin L Hoch; Elizabeth T Loggers; Eve Rodler; Janet F Eary; Ernest U Conrad; Robin L Jones; Cassian Yee
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.